Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Stoke Therapeutics Analyst Ratings and Price Targets | NASDAQ:STOK | Benzinga
Stoke Therapeutics Inc has a consensus price target of $22.25 based on the ratings of 10 analysts. The high is $47 issued by HC Wainwright & Co. on March 19, 2025. The low is $12 issued by B of A Securities on May 1, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Chardan Capital, and Needham on March 19, 2025, March 19, 2025, and March 18, 2025, respectively. With an average price target of $31 between HC Wainwright & Co., Chardan Capital, and Needham, there's an implied 292.90% upside for Stoke Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Chardan Capital
Needham
Wedbush
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Stoke Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/19/2025 | Buy Now | 495.69% | HC Wainwright & Co. | Andrew Fein57% | $47 → $47 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2025 | Buy Now | 204.18% | Chardan Capital | Rudy Li17% | $24 → $24 | Maintains | Buy | Get Alert |
| 03/18/2025 | Buy Now | 178.83% | Needham | Joseph Stringer50% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 02/19/2025 | Buy Now | 204.18% | Chardan Capital | Rudy Li17% | $24 → $24 | Maintains | Buy | Get Alert |
| 02/18/2025 | Buy Now | 178.83% | Needham | Joseph Stringer50% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 02/18/2025 | Buy Now | 495.69% | HC Wainwright & Co. | Andrew Fein57% | $35 → $47 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | $35 → $35 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | 178.83% | Needham | Joseph Stringer50% | $22 → $22 | Maintains | Buy | Get Alert |
| 12/20/2024 | Buy Now | 204.18% | Chardan Capital | Rudy Li17% | → $24 | Initiates | → Buy | Get Alert |
| 12/10/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan72% | — | Reiterates | Overweight → Overweight | Get Alert |
| 11/06/2024 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2024 | Buy Now | 178.83% | Needham | Joseph Stringer50% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | 178.83% | Needham | Joseph Stringer50% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2024 | Buy Now | 115.46% | Wedbush | Laura Chico48% | $17 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 06/28/2024 | Buy Now | 178.83% | Needham | Joseph Stringer50% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 153.49% | Canaccord Genuity | Sumant Kulkarni43% | $21 → $20 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 178.83% | Needham | Joseph Stringer50% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 178.83% | Needham | Joseph Stringer50% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan72% | — | Reiterates | → Overweight | Get Alert |
| 03/26/2024 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2024 | Buy Now | 115.46% | Wedbush | Laura Chico48% | $13 → $17 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 166.16% | Canaccord Genuity | Sumant Kulkarni43% | $18 → $21 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | 64.77% | JP Morgan | Jessica Fye68% | $6 → $13 | Maintains | Neutral | Get Alert |
| 03/26/2024 | Buy Now | — | TD Cowen | Yaron Werber35% | — | Upgrade | Hold → Buy | Get Alert |
| 03/26/2024 | Buy Now | 178.83% | Needham | Joseph Stringer50% | $14 → $22 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 77.44% | Needham | Joseph Stringer50% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | Buy Now | 77.44% | Needham | Joseph Stringer50% | $25 → $14 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 77.44% | Cantor Fitzgerald | Charles Duncan72% | $18 → $14 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 191.51% | Credit Suisse | Judah Frommer66% | → $23 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2023 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 216.86% | Needham | Joseph Stringer50% | → $25 | Reiterates | → Buy | Get Alert |
| 07/31/2023 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | Buy Now | 216.86% | Needham | Joseph Stringer50% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | Buy Now | 216.86% | Cantor Fitzgerald | Charles Duncan72% | $20 → $25 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | 254.88% | Credit Suisse | Judah Frommer66% | → $28 | Reiterates | → Outperform | Get Alert |
| 05/05/2023 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | → $35 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | 153.49% | Needham | Joseph Stringer50% | → $20 | Reiterates | → Buy | Get Alert |
| 05/01/2023 | Buy Now | 52.09% | B of A Securities | Greg Harrison48% | $9 → $12 | Upgrade | Underperform → Neutral | Get Alert |
| 04/26/2023 | Buy Now | 204.18% | Canaccord Genuity | Sumant Kulkarni43% | → $24 | Assumes | → Buy | Get Alert |
| 03/16/2023 | Buy Now | 216.86% | Needham | Joseph Stringer50% | → $25 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 153.49% | Cantor Fitzgerald | Charles Duncan72% | → $20 | Reiterates | → Overweight | Get Alert |
| 03/07/2023 | Buy Now | 216.86% | Wedbush | Laura Chico48% | $33 → $25 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | 254.88% | Credit Suisse | Judah Frommer66% | $32 → $28 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | → $35 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 216.86% | Needham | Joseph Stringer50% | → $25 | Reiterates | → Buy | Get Alert |
| 01/11/2023 | Buy Now | 305.58% | Credit Suisse | Judah Frommer66% | $38 → $32 | Maintains | Outperform | Get Alert |
| 12/05/2022 | Buy Now | 343.6% | HC Wainwright & Co. | Andrew Fein57% | $70 → $35 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 381.62% | Credit Suisse | Judah Frommer66% | $50 → $38 | Maintains | Outperform | Get Alert |
| 11/14/2022 | Buy Now | 216.86% | Needham | Joseph Stringer50% | $50 → $25 | Maintains | Buy | Get Alert |
| 08/08/2022 | Buy Now | 533.71% | Needham | Joseph Stringer50% | $65 → $50 | Maintains | Buy | Get Alert |
| 05/26/2022 | Buy Now | 381.62% | Cantor Fitzgerald | Charles Duncan72% | $68 → $38 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Stoke Therapeutics (STOK) stock?
The latest price target for Stoke Therapeutics (NASDAQ:STOK) was reported by HC Wainwright & Co. on March 19, 2025. The analyst firm set a price target for $47.00 expecting STOK to rise to within 12 months (a possible 495.69% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Stoke Therapeutics (STOK)?
The latest analyst rating for Stoke Therapeutics (NASDAQ:STOK) was provided by HC Wainwright & Co., and Stoke Therapeutics reiterated their buy rating.
When was the last upgrade for Stoke Therapeutics (STOK)?
The last upgrade for Stoke Therapeutics Inc happened on March 26, 2024 when TD Cowen raised their price target to N/A. TD Cowen previously had a hold for Stoke Therapeutics Inc.
When was the last downgrade for Stoke Therapeutics (STOK)?
There is no last downgrade for Stoke Therapeutics.
When is the next analyst rating going to be posted or updated for Stoke Therapeutics (STOK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Stoke Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Stoke Therapeutics was filed on March 19, 2025 so you should expect the next rating to be made available sometime around March 19, 2026.
Is the Analyst Rating Stoke Therapeutics (STOK) correct?
While ratings are subjective and will change, the latest Stoke Therapeutics (STOK) rating was a reiterated with a price target of $47.00 to $47.00. The current price Stoke Therapeutics (STOK) is trading at is $7.89, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.